AC
REGN icon

Arjuna Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Arjuna Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$353K Buy
457
+14
+3% +$10.7K 0.09% 99
2025
Q4 		$342K Buy
+443
New +$301K 0.08% 97
2024
Q4 		– Sell
-282
Closed -$296K – 110
2024
Q3 		$296K Buy
282
+1
+0.4% +$1.11K 0.08% 91
2024
Q2 		$295K Buy
281
+2
+0.7% +$1.94K 0.08% 92
2024
Q1 		$269K Buy
279
+18
+7% +$17.1K 0.08% 94
2023
Q4 		$229K Buy
+261
New +$215K 0.07% 89
2023
Q3 		– Sell
-1,621
Closed -$1.16M – 102
2023
Q2 		$1.16M Buy
1,621
+81
+5% +$62.5K 0.41% 65
2023
Q1 		$1.27M Buy
1,540
+281
+22% +$212K 0.5% 57
2022
Q4 		$908K Buy
+1,259
New +$929K 0.42% 62

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Arjuna Capital's REGN Position: Q1 2026 in Review

Arjuna Capital increased its Regeneron Pharmaceuticals (REGN) stake by 3.2% in Q1 2026, buying an estimated $10.7K and bringing the position to 457 shares worth $353K. The position accounts for 0.09% of the portfolio, ranked #99.

Arjuna Capital first reported a position in REGN in Q4 2022 and has held it in 9 quarters since. The position peaked at $1.27M in Q1 2023. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Arjuna Capital held 457 shares of Regeneron Pharmaceuticals worth $353K as of Q1 2026.
  • Arjuna Capital bought 14 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $10.7K.
  • Regeneron Pharmaceuticals made up 0.09% of Arjuna Capital's portfolio in Q1 2026, its #99 holding.
  • Arjuna Capital first reported a position in Regeneron Pharmaceuticals in Q4 2022 and has held it in 9 quarters since.
  • Arjuna Capital's Regeneron Pharmaceuticals position peaked at $1.27M in Q1 2023.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Arjuna Capital's 13F filing for Q1 2026, filed 6 May 2026.